Lumenis presented its FoLix, an FDA-cleared fractional laser for hair loss treatment, at the 2025 American Academy of Dermatology Annual Meeting that took place on March 7-10 at the Orlando Convention Center. During the FoLix panel symposium, titled “Unlocking New Possibilities in Hair Loss Treatment,” attendees learned about the future of hair loss treatment, including emerging trends, breakthrough technologies and how providers can enhance their treatment portfolio.
Lumenis presented its FoLix, an FDA-cleared fractional laser for hair loss treatment, at the 2025 American Academy of Dermatology Annual Meeting that took place on March 7-10 at the Orlando Convention Center. During the FoLix panel symposium, titled “Unlocking New Possibilities in Hair Loss Treatment,” attendees learned about the future of hair loss treatment, including emerging trends, breakthrough technologies and how providers can enhance their treatment portfolio.
The FoLix utilizes a non-ablative fractional laser, delivering laser energy for dermal coagulation that activates the body’s own natural healing process. This boosts blood flow, cytokine activity and hair follicle stimulation, says Laarni Cayetano, vice president of marketing at Lumenis.
“FoLix harnesses Lumenis’ proprietary technology to deliver non-ablative coagulative arrays of 110µm microbeams in a fractional manner,” says Cayetano. “The laser creates columns of controlled coagulative zones while sparing the tissue surrounding the columns, ensuring optimal irradiance and area coverage by homogenous placement of the laser’s micro-beams onto the tissue.”
This heating from the laser reaches the mid-reticular dermis, serving as the stimulus for inflammatory mediator release, fibroblast activation, neocollagenesis and dermal remodeling. The FoLix stimulates blood flow and triggers the natural wound healing process to activate a growth factor and drive hair follicle stimulation.
“As the stratum corneum remains intact, the skin maintains its defense function to microbial infection and highly minimizes the risk of potential side effects as compared to ablative techniques and eludes the need for postoperative wound care,” Cayetano says.
Built into the laser is a FoliCool tip that cools the treated area to improve scalp hair appearance. Cayetano says the FoLix can produce results from 4-6 monthly sessions with no chemicals, needles, anesthesia, surgery or downtime.
“FoLix is about more than just hair; it’s about having the self-confidence to live life to the fullest,” she says. “Lumenis is investing in the further understanding of hair loss and remains focused on developing innovative hair loss treatment options to improve overall patient care.
